Tol, H. van

imatinib accumulation resistance cancer substrate mitoxantrone protein mesylate figure cancer res imatinib accumulation blood leukemia 15 m imatinib inhibitor doxorubicin efflux hek 293 cells tumor variant transporter imatinib mesylate intracellular breast control transport figure 1 bcrp-mediated mechanism subline result netherland mcf 7 sublines figure 1 e tyrosine kinase inhibitor expression tumor cells panel mcf 7 2- hour exposure mutation 14 c-labeled imatinib 2 hours fluorescence intensity treatment 20 000 events wt-bcrp bcrp-overexpressing 293/neo mt-bcrp tyrosine specificity effect 7/advp methotrexate burger level kinase imatinib uptake bcrp /abcg fluorescence nooter k 293/g 293/r sawyers cl american society doxorubicin accumulation myeloid leukemia cytometry stromal drug transporters pcdna 3 bcrp-mediated efflux bcrp efflux sn -38 fraction substrate specificity addition codon 482 judson i